MedTrace Logo

A Prospective Study to Observe Adverse Effects in Patients Receiving Anti-PD1 Immunotherapy

NCT05669638 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2024-02-09

No results posted yet for this study

Summary

The goal of this observational study is to learn about in the development process of adverse reactions of anti-PD1 immunotherapy. The main question it aims to observe:

* The autoantibody profile of patients
* The adverse reactions of patients
* The changes of immune cells and cytokine in patients

Conditions

  • Immunotherapy
  • ADR

Sponsors & Collaborators

  • Xuanwu Hospital, Beijing

    lead OTHER

Principal Investigators

  • Hongyan Li, MD,PhD · Xuanwu Hospital, Beijing

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2025-05-01
Completion
2025-05-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05669638 on ClinicalTrials.gov